CA
NZ
UK
AU
IND
US
Yoon Yoon Soo (Gene), a director and 10% owner of Acushnet Holdings Corp., filed a statement of changes in beneficial ownership with the SEC on September 22, 2026, disclosing a transaction dated September 18, 2026.
A Form 4 filed with the SEC on September 22, 2026 discloses that Gregory A. Hewett, a director of Acushnet Holdings Corp. (NYSE:GOLF), acquired 101.69 shares of common stock on September 18, 2026 through dividend equivalent rights accrued on deferred restricted stock units.
Director Steven Tishman filed a Form 4 with the SEC on September 22, 2026, reporting the acquisition of common stock in Acushnet Holdings Corp. (NYSE:GOLF) on September 18, 2026, through dividend equivalent rights accrued on deferred restricted stock units.
Josh D. Paul, Chief Accounting Officer of Palo Alto Networks Inc., filed a Form 4 on September 22, 2026, disclosing the acquisition of 7,211 restricted stock units in a transaction dated September 18, 2026.
A Form 4 filed on September 22, 2026, disclosed that Yvonne Greenstreet, Chief Executive Officer and Director of Alnylam Pharmaceuticals, Inc., acquired 107 shares of common stock on September 19, 2026, in connection with a 10-year continuous employment recognition award.
Dorita Gilinski, a director of GeoPark Ltd (NYSE:GPRK), filed a Form 4 on September 22, 2026, reporting the acquisition of 4,224 common shares on September 21, 2026.
Rocio Martin Hoyos, Chief Strategy Officer of Atrium Therapeutics, Inc., filed a statement of changes in beneficial ownership on September 22, 2026, disclosing a transaction in common stock dated September 18, 2026.
Brendan R. Winslow, Chief Financial Officer of Atrium Therapeutics, Inc., filed a statement of changes in beneficial ownership on September 22, 2026, reporting a transaction dated September 18, 2026, involving the withholding of common shares to cover tax obligations tied to vesting restricted stock …
Stephanie Kenney, Chief Corporate Affairs Officer of Atrium Therapeutics, Inc., filed a statement of changes in beneficial ownership on September 22, 2026, reporting a transaction dated September 18, 2026, involving common stock of the company.
Kathleen P. Gallagher, Chief Executive Officer and President of Atrium Therapeutics, Inc., filed a Form 4 on September 22, 2026, reporting a disposition of common stock on September 18, 2026, related to the vesting of restricted stock units.
Please wait processing your request...